moxifloxacin has been researched along with reserpine in 11 studies
| Studies (moxifloxacin) | Trials (moxifloxacin) | Recent Studies (post-2010) (moxifloxacin) | Studies (reserpine) | Trials (reserpine) | Recent Studies (post-2010) (reserpine) |
|---|---|---|---|---|---|
| 3,157 | 552 | 1,690 | 15,546 | 223 | 436 |
| Protein | Taxonomy | moxifloxacin (IC50) | reserpine (IC50) |
|---|---|---|---|
| Bile salt export pump | Homo sapiens (human) | 8.7875 | |
| ATP-dependent translocase ABCB1 | Homo sapiens (human) | 3.2092 | |
| Quinolone resistance protein NorA | Staphylococcus aureus | 8.5429 | |
| Mu-type opioid receptor | Homo sapiens (human) | 4.152 | |
| Chromaffin granule amine transporter | Homo sapiens (human) | 0.05 | |
| Synaptic vesicular amine transporter | Rattus norvegicus (Norway rat) | 0.0034 | |
| Synaptic vesicular amine transporter | Homo sapiens (human) | 0.0147 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (9.09) | 18.2507 |
| 2000's | 4 (36.36) | 29.6817 |
| 2010's | 6 (54.55) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Arpin, C; Ba, BB; Caignard, DH; Forfar-Bares, I; Grellet, J; Guillon, J; Jarry, C; Moreau, S; Quentin, C; Vidaillac, C | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Brincat, JP; Carosati, E; Dimovska, M; Fravolini, A; Kaatz, GW; Massari, S; Pieroni, M; Sabatini, S | 1 |
| Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Engler, B; Fluit, AC; Hadding, U; Heinz, HP; Hofmann, B; Jones, ME; Lückefahr, M; Schmitz, FJ; Verhoef, J | 1 |
| Beyer, R; Millichap, JJ; Noskin, GA; Pestova, E; Peterson, LR; Stosor, V | 1 |
| Millichap, JJ; Noskin, GA; Pestova, E; Peterson, LR | 1 |
| Drudy, D; Fanning, S; Kyne, L; O'Gaora, P; O'Mahony, R; Quinn, T | 1 |
| Gumbo, T; Leff, R; Meek, C; Pasipanodya, J; Sherman, CM; Srivastava, S | 1 |
| Chien, JY; Hsueh, PR; Yu, CJ | 1 |
1 review(s) available for moxifloxacin and reserpine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
10 other study(ies) available for moxifloxacin and reserpine
| Article | Year |
|---|---|
Synthesis of omeprazole analogues and evaluation of these as potential inhibitors of the multidrug efflux pump NorA of Staphylococcus aureus.
Topics: Anti-Bacterial Agents; Bacterial Proteins; Culture Media; Drug Resistance, Multiple, Bacterial; Enzyme Inhibitors; Indicators and Reagents; Kinetics; Microbial Sensitivity Tests; Multidrug Resistance-Associated Proteins; Norfloxacin; Omeprazole; Staphylococcus aureus; Structure-Activity Relationship | 2007 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
From 6-aminoquinolone antibacterials to 6-amino-7-thiopyranopyridinylquinolone ethyl esters as inhibitors of Staphylococcus aureus multidrug efflux pumps.
Topics: Aminoquinolines; Anti-Bacterial Agents; Drug Resistance, Multiple; Esters; Ethidium; Genes, MDR; Microbial Sensitivity Tests; Staphylococcus aureus; Structure-Activity Relationship | 2010 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
The effect of reserpine, an inhibitor of multidrug efflux pumps, on the in-vitro activities of ciprofloxacin, sparfloxacin and moxifloxacin against clinical isolates of Staphylococcus aureus.
Topics: Anti-Infective Agents; Aza Compounds; Ciprofloxacin; Drug Resistance, Microbial; Fluoroquinolones; Genes, Bacterial; Humans; Methicillin Resistance; Microbial Sensitivity Tests; Moxifloxacin; Mutation; Polymerase Chain Reaction; Quinolines; Reserpine; Staphylococcal Infections; Staphylococcus aureus | 1998 |
A convenient assay for estimating the possible involvement of efflux of fluoroquinolones by Streptococcus pneumoniae and Staphylococcus aureus: evidence for diminished moxifloxacin, sparfloxacin, and trovafloxacin efflux.
Topics: Anti-Infective Agents; Aza Compounds; Drug Resistance, Microbial; Fluoroquinolones; Microbial Sensitivity Tests; Moxifloxacin; Naphthyridines; Quinolines; Reserpine; Staphylococcus aureus; Streptococcus pneumoniae | 2000 |
Intracellular targets of moxifloxacin: a comparison with other fluoroquinolones.
Topics: Anti-Infective Agents; Aza Compounds; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Drug Resistance, Microbial; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Moxifloxacin; Mutation; Pneumococcal Infections; Polymerase Chain Reaction; Quinolines; Reserpine; Sequence Analysis, DNA; Streptococcus pneumoniae | 2000 |
High-level resistance to moxifloxacin and gatifloxacin associated with a novel mutation in gyrB in toxin-A-negative, toxin-B-positive Clostridium difficile.
Topics: Amino Acid Substitution; Anti-Bacterial Agents; Aza Compounds; Bacterial Proteins; Bacterial Toxins; Clostridioides difficile; Dipeptides; DNA Gyrase; DNA, Bacterial; Drug Resistance, Bacterial; Enterotoxins; Enzyme Inhibitors; Fluoroquinolones; Gatifloxacin; Microbial Sensitivity Tests; Molecular Sequence Data; Moxifloxacin; Mutation; Polymerase Chain Reaction; Quinolines; Reserpine; Ribotyping; Sequence Analysis, DNA; Verapamil | 2006 |
Rapid drug tolerance and dramatic sterilizing effect of moxifloxacin monotherapy in a novel hollow-fiber model of intracellular Mycobacterium kansasii disease.
Topics: Anti-Bacterial Agents; Area Under Curve; Colony Count, Microbial; Dose-Response Relationship, Drug; Fluoroquinolones; Lung Diseases; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium Infections, Nontuberculous; Mycobacterium kansasii; Reserpine; Sterilization | 2015 |
High incidence of fluoroquinolone resistance and effect of efflux pump inhibitors on moxifloxacin resistance among Mycobacterium tuberculosis isolates causing urinary tract infection in Taiwan.
Topics: Anti-Bacterial Agents; Biological Transport, Active; Carbonyl Cyanide m-Chlorophenyl Hydrazone; DNA Gyrase; Drug Resistance, Bacterial; Enzyme Inhibitors; Fluoroquinolones; Humans; Incidence; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium tuberculosis; Prevalence; Reserpine; Taiwan; Tuberculosis, Urogenital; Verapamil | 2017 |